TABLE 1.

Demographics and treatment data

	Age at pri. dx (yrs)	Sex	Histologic subtype (fusion status) [pri. site]	Metastatic disease at pri. diagnosis	Primary chemo regimen	Time to relapse (mo)	Site of relapse	VIT line of tx	VIT regimen useda	Cycles of VITb	Local control	Reason for stopping chemo	Best response to therapy	Length of follow-up from date of relapse/start of VIT (mo)	Status at last follow-up
1	8	M	Emb [GU]	No	VAC	12	Local	4	1–50 mg/m2 IV × 5 days T-150 mg/m2 × 5 days	2	RT	PD	PD	12/2.4	DOD
2	5	F	Emb [HN non-PM]	No	VAC	9	Local	2	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	1	None	PD	PD	3/2.7	DOD
3	14	F	Alv(+) [trunk]	No	VAC	16	Distant (bone)	2	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	1	RT	Toxicity	PD	4/1.2	DOD
4	17	F	Emb [GU non-B/P]	No	VAC, VA	46	Distant (brainstem)	2	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	6	RT	End of therapy	SD	17/16.6	DOD
5	10	F	Emb [GU non-B/P]	No	VAC	3	Local	3	1–100 mg/m2 PO × 10 days T-100 mg/m2 × 5 days	2	None	PD	PD	28/11.0	DOD
6	8	M	Emb [orbit-PM]	No	VAC	12	Local	3	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	2	None	PD	PD	7/4.9	DOD
7	9	M	Emb [HN non-PM]	No	VAC	27	Local	2	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	18	S + RT	End of therapy	Not evaluablec	34/33.5	Alive, on hospice care
8	9	M	Alv(unk) [extremity]	Yes	ARST0431	10	Lung	4	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	2	None	PD	PD	11/7.4	DOD
9	4	M	Emb [cheek, PM]	Yes	ARST08P1	10	Lung	1	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	2	RT	End of therapy	PD	2/12.6	DOD
10	14	F	Alv(unk) [trunk]	No	VAC	13	Distant (lung, bone)	2	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	1	RT	Toxicity	Not evaluablec	2/7.1	DOD
11	7	M	Emb [GU non-B/P]	No	VAC	13	LN	1	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	1	S + RT	PD	PD	23/23.0	DOD
12	1.75	F	Alv (+) [HN non-PM]	No	VAC	16	Local	1	1–90 mg/m2 PO × 5 days T-100 mg/m2 × 5 days	12	S	Physician preference	Not evaluablec	31/31.0	Alive without disease
13	7	M	Emb [pelvis]	No	VAC	23	Distant (liver)	3	1–20 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	9	S	PD	SD	27/9.4	DOD
14	9	F	Alv (unk) [extremity]	No	VAC	33	Lung	3	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	1	None	PD	PD	9/2.0	DOD
15	4	M	Emb [orbit-PM]	No	VAC	6	Local	3	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	2	None	PD	PD	6/2.7	DOD
16	16	M	Alv (+) [cervical with LN]	Yes	ARST0431	22	Max sinus	2	1–90 mg/m2 PO × 5 days T-150 mg/m2 × 5 days	6	RT	PD	SD	17/8.6	Alive with disease
17	13	M	Emb [GU non-B/P]	No	VAC	35	Distant (lung, bone, LN, abdomen)	2	1–70 mg/m2 PO × 5 days T-125 mg/m2 × 5 days	2	None	PD	PD	10/2.6	DOD
18	4	M	Emb [GU non-B/P]	No	VA	18	Abdomen	1	1–50 mg/m2 IV × 5 days T-100 mg/m2 × 5 days	6	S	Last follow-up	Not evaluablec	4/4.0	Alive without disease
19	4	M	Alv (+) [cheek/mandible-PM]	No	VAC	17	Local, LN	3	1–90 mg/m2 PO × 5 days T-150 mg/m2 × 5 days	7	None	PD	SD	20/14.8	Alive with disease

Yrs, years, mo, months; pri. Dx, primary diagnosis; Pri. Site, primary site; tx, treatment; M, male; F, female; Emb, embryonal; Alv, alveolar; unk, unknown; pos, positive; GU, genitourinary; HN non-PM, head and neck nonparameningeal; PM, parameningeal; LN, lymph node; VAC, vincristine, actinomycin, cyclophosphamide; VA, vincristine, actinomycin; I, irinotecan; T, temozolomide; IV, intravenous; PO, per oral; S, surgery; RT, radiotherapy; CR, complete response; SD, stable disease; PD, progressive disease; DOD, died of disease.

^aAll except patient 8 received vincristine 0.5 mg/m².

^bNumber.

^cVIT used as adjuvant therapy, response not evaluable.